If you can't see this email correctly, click here.
Reading Deals - How to Interpret Licese Deals

The following article gives a guideline on how to interpret press releases on license deals.

  Non-Dilutive Financing Alternatives

The common way to raise capital in equity rounds is for many companies unattractive because they cannot get a fair valuation. Consequently, the new investors would excessively dilute existing shareholders. In the biotech industry companies have various alternatives to equity financing that limit dilution of shareholders. The following article gives a brief overview of pros and cons of the different financing alternatives.

San Francisco 6th June - San Diego 16th June 2008

Pre- BIO Workshop: License Contract Valuation in Excel

Professional valuation in your hands

The leading valuation solution again got better. Avance releases ri:val v2.5 featuring:

  • Investors can analyze their portfolio of different companies in terms of risk profile, value, value components, diversification, and cluster risks. Fund valuation and monitoring becomes an easy task.
  • Technology transfer offices now use ri:val to value their portolio of license contracts and equity participations in spin-outs. The user friendly structure of ri:val allows fast and complete valuations for licensing, monitoring, and communication purposes.


The guide to valuation in pharma and biotech. Become an expert yourself.

> www.avance.ch
> www.rival.ch
You can sign up for News in Avance, change your e-mail address, or unsubscribe on our newsletter here.
Copyright: Avance, Basel GmbH - Bäumleingasse 2 - CH - 4051 Basel